Not available

General Information


DRACP ID  DRACP01763

Peptide Name   Not available

Sequence  GTGKA

Sequence Length  5

UniProt ID  Not available

PubChem CID  Not available

Origin  Not available

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
Malme-3M Melanoma Carcinoma As show in fig 8, peptide reduced a size of the tumor due to the cancer cell strains Tumor growth assay Not available Patent
SNU38R Melanoma Carcinoma As show in fig 8, peptide reduced a size of the tumor due to the cancer cell strains Tumor growth assay Not available Patent

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01763

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C17H32N6O7

Absent amino acids  CDEFHILMNPQRSVWY

Common amino acids  G

Mass  50401

Pl  9.7

Basic residues  1

Acidic residues  0

Hydrophobic residues  1

Net charge  1

Boman Index  -443

Hydrophobicity  -72

Aliphatic Index  20

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US2018/0085422A1

Patent Title  Compositions for Overcoming Anti-Cancer Drug-Resistance or Compositions for Anti-Cancer Activity Employing Cage-Derived Peptides

Other Iinformation  Patent Application; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Active; Application No: 201514978256; Filed: Dec 22, 2015; Published: Mar 29, 2018; Earliest Priority: Dec 22, 2015; Granted: Jul 21, 2020

Other Published ID  US10716826B2  




DRACP is developed by Dr.Zheng's team.